• ATRIVA Therapeutics

    First-in-class host-targeting antiviral therapies against severe respiratory viral infections, including influenza and potentially coronaviruses.


    Great potential against influenza virus due to antiviral and immunomodulating activity of ATRIVA’s lead product ATR-002.

    Phase I clinical trial successfully completed, Phase II in influenza under preparation.


    Learn more


  • ATRIVA Therapeutics

    Invest in research to contribute to pandemic preparedness!


    We invite you to explore our approach and development milestones presented on this website and encourage you to contact us directly.


    Get in touch


  • 1
  • 2
  • First-in-class host-targeting antiviral therapies against severe respiratory viral infections, including influenza and potentially coronaviruses.

    Learn more
  • Invest in research to contribute to pandemic preparedness!

    Get in touch
  • 1
  • 2

About Us

Learn more about the team behind ATRIVA Therapeutics GmbH.

 

Read more

The ATRIVA Approach

Novel host-targeting approach to prevent viral replication.

 

Read more

  • News
  • Atriva Therapeutics to present at the BIO-Europe in Hamburg

Atriva Therapeutics to present at the BIO-Europe in Hamburg

Tübingen (Germany), October 31, 2019 – Atriva Therapeutics GmbH, a biopharma­ceutical company pioneering the development of host-targeting antiviral therapies, will present at the upcoming 25th Annual International Partnering Conference BIO-Europe®.

The conference is held at the Hamburg Messe in Hamburg, Germany, from November 11th – 13th, 2019. During the conference, CEO Dr. Rainer Lichtenberger and COO Dr. Christian Wallasch will represent the Company and be available for networking and one-on-one meetings. Dr. Lichtenberger will also give a Company Presentation as part of the Infectious Disease Session on November 11, at 17:45. The session will take place in Level 1, Hall B1, Room 7. 

 

About Atriva Therapeutics GmbH

Atriva Therapeutics, founded in 2015, is a biopharmaceutical company pioneering the development of host-targeting antiviral therapies setup by a team of leading scientists in viral research and seasoned industry experts. The company aims to develop new antiviral therapies against different respiratory viral infections. The lead product ATR-002 is a first-in-class host-targeting agent, inhibiting viral replication in influenza and other respiratory infections, an area of high unmet medical need. ATR-002 is under clinical development in a Phase I trial to evaluate safety and tolerability in healthy subjects. The Company owns nine broad patent families with broad coverage related to the use of MEK inhibitors and other kinase inhibitors for anti-viral therapies. The patent life runs through 2039. Atriva Therapeutics is located in Tübingen and Frankfurt, Germany.

For further information, please visit www.atriva-therapeutics.com or see our LinkedIn profile  Atriva Therapeutics GmbH.

Contact:

Atriva Therapeutics GmbH
Dr. Rainer Lichtenberger, CEO
phone: +49 7071 859 7673

mobile: +49 173 743 1897

This email address is being protected from spambots. You need JavaScript enabled to view it.

Media and Investor Relations:

MC Services AG

Raimund Gabriel / Eva Bauer

phone: +49 (0)89 21022880

This email address is being protected from spambots. You need JavaScript enabled to view it.

Latest News

Contact Form

Please, enter your name
Please, enter your phone number
Please, enter your e-mail address Mail address is not not valid
Please, enter your message

Address

Atriva Therapeutics GmbH
Christophstr. 32, 72072 Tübingen

+49 (0)7071 8597673
info@atriva-therapeutics.com

LinkedIn
Twitter

In order to be able to design our website in the best possible way and to continuously improve it, we are using cookies. By continuing to use our website, you permit the use of cookies. More information can be found in our data protection rules.